NONMEM Users Network Archive

Hosted by Cognigen

RE: NM7 question

From: Sam Liao <sliao>
Date: Wed, 4 Nov 2009 21:03:59 -0500

Dear Robert:

 

Thanks for your kindly reply. I tried either one of the following two
methods to run M3 method to handle BQL samples, it failed to run. I got
error msg as shown below the method. I also tried SAEM, they all said the
same thing - " WITH NMPR17, LAPLACIAN ESTIMATION METHOD MUST BE USED"

 

Sam Liao

Pharmax Research

============================================================================
==

$EST METHOD=IMP INTERACTION NITER=200 CTYPE=3 ISAMPLE=1000 PRINT=10 NOABORT
SIGL=3 SIG=1

$EST METHOD=BAYES INTERACTION NBURN=100 NSAMPLE=3000 NOABORT FILE=RUN301.TXT


============================================================================
==

 

 MONITORING OF SEARCH:

 

0PROGRAM TERMINATED BY OBJ2

 WITH INDIVIDUAL 1 ID= 2.00000000000000E+00 DATA REC. 3

 WITH NMPR17, LAPLACIAN ESTIMATION METHOD MUST BE USED

 iteration 0 OBJ= 0.000000000000000E+000

 

From: Bauer, Robert [mailto:Robert.Bauer
Sent: Wednesday, November 04, 2009 7:50 PM
To: Sam Liao; nmusers
Subject: RE: [NMusers] NM7 question

 

Yes

 

Robert J. Bauer, Ph.D.
Vice President, Pharmacometrics
ICON Development Solutions

Tel: (215) 616-6428
Mob: (925) 286-0769
Email: Robert.Bauer
Web: www.icondevsolutions.com

 

 

 

 

  _____

From: owner-nmusers
Behalf Of Sam Liao
Sent: Wednesday, November 04, 2009 7:31 PM
To: 'nmusers'
Subject: [NMusers] NM7 question

Dear NONMEM team:

To run the M3 method to handle BQL samples, we have to use method=LAPLACIAN
NUMERICAL SLOW in NM6. Can we use the new methods in NM7 such as IMP, SAEM
or BAYES if we have to run the M3 method?

 

Best regards,

Sam Liao

Pharmax Reseach

 

From: owner-nmusers
Behalf Of Nick Holford
Sent: Wednesday, November 04, 2009 6:43 PM
To: nmusers
Subject: Re: [NMusers] advan8 vs. advan13 (CORRECTION)

 

Hi,

Thanks to Peiming Ma and Thuy Vu for pointing out an error in my attempt to
transform bioavailability into its logit.

The logit transformation of a probability is ln(P/(1-P)) i.e. the log of the
odds ratio. The reverse transform is correct i.e. exp(logit) is the odds
ratio and P is then OR/(1+OR) (or 1/1+exp(-logit)).

If THETA(1) is the bioavailability then this is (I hope) the correct
transformation of THETA(1) and reverse transform to get the individual
bioavailability with a random effect constrained to be within 0 and 1.

MU_1=LOG(THETA(1)/(1-THETA(1)) ; logit of population bioavailability

EXPP=MU_1+ETA(1) ; add random effect

BIO=1/(1+EXP(-EXP(EXPP))) ; individual bioavailability


Nick

--
Nick Holford, Professor Clinical Pharmacology
Dept Pharmacology & Clinical Pharmacology
University of Auckland,85 Park Rd,Private Bag 92019,Auckland,New Zealand
tel:+64(9)923-6730 fax:+64(9)373-7090 mobile:+64(21)46 23 53
email: n.holford
http://www.fmhs.auckland.ac.nz/sms/pharmacology/holford
ICON plc made the following annotations.
----------------------------------------------------------------------------
--
This e-mail transmission may contain confidential or legally privileged
information
that is intended only for the individual or entity named in the e-mail
address. If you
are not the intended recipient, you are hereby notified that any disclosure,
copying,
distribution, or reliance upon the contents of this e-mail is strictly
prohibited. If
you have received this e-mail transmission in error, please reply to the
sender, so that
ICON plc can arrange for proper delivery, and then please delete the
message.
Thank You,
ICON plc
South County Business Park
Leopardstown
Dublin 18
Ireland
Registered number: 145835
 

Received on Wed Nov 04 2009 - 21:03:59 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com.

Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.